Teneliximab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 03:51, 12 September 2020 (Alter: isbn. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:Chemicals that do not have a ChemSpider ID assigned | via #UCB_Category). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Teneliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetCD40
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40. As of 2009, it has not entered clinical trials.[2]

References

  1. ^ International Nonproprietary Names For Pharmaceutical Substances
  2. ^ Iqbal S. Grewal, ed. (January 15, 2009). Therapeutic Targets of the TNF Superfamily (Advances in Experimental Medicine and Biology). Springer. p. 22. ISBN 978-0-387-89519-2.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Teneliximab&oldid=977977998"